Senzime publishes annual and sustainability report for 2023

Rhea-AI Summary

Senzime AB (SNZZF) announces the publication of its 2023 annual and sustainability report, highlighting a remarkable 150% revenue increase to 36 million SEK. The growth was fueled by significant hospital contract wins and sensor sales. CEO Philip Siberg expressed optimism about the company's performance in 2023.

Positive

• Revenue surged by over 150% to 36 million SEK in 2023.
• Significant growth attributed to major hospital contract wins and sensor sales.
• CEO Philip Siberg optimistic about the company's performance in 2023.

Negative

• None.

UPPSALA, SE / ACCESSWIRE / April 24, 2024 / Senzime (STO:SEZI)(OTCQX:SNZZF) Senzime AB (publ) announces today that the company's annual and sustainability report for 2023 is published and available at the website www.senzime.com.

"2023 was a commerical breakthrough year for Senzime. Revenues increased by more than 150 percent to reach 36 million SEK. Growth was driven by major hospital contract wins and recurring sensor sales", commented Philip Siberg, CEO of Senzime

For further information, please contact:

Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com

Slavoljub Grujicic, CFO
Phone: +46 (0) 76 306 60 11, e-mail: slavoljub.grujicic@senzime.com

About Senzime

Senzime, headquartered in Sweden, is a leading medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. The company provides an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for accurate monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world's leading markets. The company's shares are listed on Nasdaq Stockholm Main Market (Nasdaq: SEZI) and cross-traded in the US on the OTCQX market (OTCQX: SNZZF). More information is available at senzime.com.

This information is information that Senzime is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-04-24 13:00 CEST.

Attachments

Annual Report 2023 EN

SOURCE: Senzime

View the original press release on accesswire.com

FAQ

What is the ticker symbol for Senzime AB?

The ticker symbol for Senzime AB is SNZZF.

What was the revenue increase percentage for Senzime AB in 2023?

Senzime AB experienced a revenue increase of more than 150% in 2023, reaching 36 million SEK.

Who commented on Senzime AB's performance in 2023?

Philip Siberg, the CEO of Senzime AB, commented on the company's performance in 2023.

Where can the annual and sustainability report for Senzime AB be found?

The annual and sustainability report for Senzime AB can be accessed on the website www.senzime.com.

What drove the growth for Senzime AB in 2023?

The growth for Senzime AB in 2023 was driven by major hospital contract wins and recurring sensor sales.